• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

    10/17/24 8:35:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZR alert in real time by email

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property.

    After careful consideration and with the assistance of its independent financial and legal advisors, the Board unanimously concluded that the Concentra proposal substantially undervalues the Company. The proposal would result in an implied equity value for Kezar stockholders that is materially below Kezar's available liquidity and fails to provide adequate value to reflect the significant potential of zetomipzomib as a therapeutic candidate. Accordingly, the Board determined that the proposal is not in the best interests of Kezar and its stockholders. In addition, in response to Concentra's proposal and Concentra and its affiliates' rapid accumulation of 9.9% of Kezar's outstanding common stock, the Board has adopted a limited duration stockholder rights plan, effective immediately (the "Rights Plan").

    "Kezar continues to experience a significant and ongoing dislocation in the trading price of its common stock which does not reflect its fundamental value," said Graham Cooper, Chairman of the Board. "We intend the Rights Plan to enable all of our stockholders to realize the long-term value of their investment. The Rights Plan should reduce the likelihood that any person or group gains control of Kezar through open market accumulation without paying all stockholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of all stockholders."

    The Rights Plan does not prevent the Board from engaging with parties or accepting an acquisition proposal, including from Concentra, if the Board believes that it is in the best interests of Kezar and all of its stockholders. The Rights Plan is similar to other plans adopted by publicly held companies in comparable circumstances, and does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future Board to redeem the rights.

    In connection with the adoption of the Rights Plan, the Board declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of Kezar's common stock as of the close of business on October 28, 2024, the record date. The Rights will be exercisable only if a person or group (an "Acquiring Person") acquires or launches a tender or exchange offer to acquire beneficial ownership (which includes certain synthetic equity interests) of 10% or more of Kezar's outstanding common stock (15% in the case of a passive institutional investor as described in the Rights Plan). Any stockholders with beneficial ownership of Kezar's outstanding common stock above the applicable threshold as of the time of this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Plan. Once the Rights become exercisable, each Right will entitle its holder (other than any Acquiring Person, whose Rights will become void) to purchase, for $7.16, additional shares of Kezar's common stock having a market value of twice such exercise price. In addition, the Rights Plan has customary flip-over and exchange features.

    The Rights Plan will expire on October 17, 2025, unless the Rights are earlier redeemed or exchanged by Kezar.

    Kezar stockholders do not need to take any further action at this time.

    Additional information regarding the Rights Plan will be contained in a Form 8-K to be filed by Kezar with the U.S. Securities and Exchange Commission.

    About Kezar Life Sciences

    Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.

    Cautionary Note on Forward-looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's future results or performance to differ materially from those expressed or implied by the forward-looking statements. There can be no assurance that the non-binding proposal or any other acquisition proposal will result in a formal offer or that any such offer will ultimately result in a completed transaction. Many factors may cause differences between current expectations and actual results, including those factors that are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241017339321/en/

    Get the next $KZR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • Why did Kezar Life Sciences reject Concentra's acquisition proposal?

      Kezar Life Sciences' Board rejected Concentra's acquisition proposal due to its significantly undervalued offer and its failure to reflect the potential of their drug candidate, zetomipzomib.

    • What is the purpose of the Rights Plan adopted by Kezar Life Sciences?

      The Rights Plan will allow existing stockholders to maintain control and prevent any single entity from acquiring a significant ownership stake without a proper premium, while still permitting discussions with other potential acquirers if it benefits stockholders.

    • When does the Rights Plan adopted by Kezar expire?

      The Rights Plan will expire on October 17, 2025, unless it is redeemed or exchanged earlier by the company.

    • How does the Rights Plan affect current stockholders of Kezar Life Sciences?

      Under the Rights Plan, current stockholders are grandfathered at their current ownership levels but cannot increase their holdings beyond the owned percentage without triggering the plan's provisions.

    • Do Kezar stockholders need to take any action in response to the Rights Plan?

      Kezar Life Sciences does not currently require any action from stockholders regarding the Rights Plan, but further information will be provided in a Form 8-K filing with the SEC.

    Recent Analyst Ratings for
    $KZR

    DatePrice TargetRatingAnalyst
    8/11/2023$4.00Overweight → Equal Weight
    Wells Fargo
    3/16/2023Outperform → Mkt Perform
    William Blair
    12/8/2021$19.00Overweight
    Wells Fargo
    11/16/2021$12.00 → $20.00Buy
    HC Wainwright & Co.
    7/20/2021$14.00Buy
    JonesTrading
    More analyst ratings

    $KZR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kezar Life Sciences downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00

      8/11/23 7:45:02 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences downgraded by William Blair

      William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

      3/16/23 7:29:33 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kezar Life Sciences with a new price target

      Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00

      12/8/21 7:24:52 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

      Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

      3/25/25 7:30:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA trial, a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH. Additionally, the event will feature presentations from Craig Lammert, MD, Associate Professor of

      3/24/25 8:00:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present at a virtual Key Opinion Leader (KOL) event hosted by William Blair on zetomipzomib clinical development in autoimmune hepatitis (AIH) and will also provide a safety update from the PALIZADE Phase 2b clinical trial in patients with active lupus nephritis (LN) on Thursday, February 27, 2025, at 4:00 p.m. ET. The event will feature Aparna Goel, MD, a general transplant and hepatologist at Stanford University, who will discuss the burden of autoimmune hepatitis (AIH) on patients, curre

      2/18/25 4:01:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Kezar Life Sciences Inc.

      SC 13D - Kezar Life Sciences, Inc. (0001645666) (Subject)

      10/8/24 4:20:17 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kezar Life Sciences Inc.

      SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

      7/8/24 4:32:39 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kezar Life Sciences Inc. (Amendment)

      SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

      2/14/24 6:47:29 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Leadership Updates

    Live Leadership Updates

    See more
    • Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

      Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Director, Christopher Kirk, PhD, appointed as Chief Executive Officer   Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment

      10/3/23 4:10:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

      Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and marketable securities totaled $306.8 million as of June 30, 2022 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. "The second quarter was tremendously productive for Kezar, during which we achieved key clinical milestone

      8/11/22 4:01:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Kezar Life Sciences, Inc., (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company's Chief Business Officer, the Compensation Committee of the company's Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. In addition, the Compensation Committee of the company's Board of Directors granted

      8/3/22 4:30:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Financials

    Live finance-specific insights

    See more
    • Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

      Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

      3/25/25 7:30:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the a

      10/17/24 8:35:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. "The goal of Kezar's R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar's

      3/13/23 7:00:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Kezar Life Sciences Inc.

      DEFA14A - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/25/25 4:12:43 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Kezar Life Sciences Inc.

      DEF 14A - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/25/25 4:10:58 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/1/25 4:05:51 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Chiang Pichi Luo claimed ownership of 2,975 shares (SEC Form 3)

      3 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/16/25 4:41:19 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider To Zung Phoung

      3 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/16/25 4:39:49 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Schiller Mark C.

      4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/1/25 8:42:03 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care